がん悪液質用薬：アナモレリン
がん悪液質用薬：アナモレリン: Cahexiaは、除脂肪体重減少と食思不振を伴う状態で、がん進行期に多い。
anamorelin (ONO‐7643)は新しいselective ghrelin receptor agonist
非がん患者含めてのシステマティック＆メタアナリシス
Two ghrelin receptor agonists for adults with malnutrition: a systematic review and meta-analysis
Jianhua Su, et al.
Nutr J. 2016; 15: 97. Published online 2016 Nov 16. doi: [10.1186/s12937-016-0214-5]
除脂肪体重増加確認されている
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112740/
(上から２番目は、透析患者・・・ J Am Soc Nephrol. 2005 Jul;16(7):2111-8. Epub 2005 May 11.）
以下は、非小細胞性肺癌NSCLC患者でのアナモレリンのRCT
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
Dr Jennifer S Temel, M et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00558-6/fulltext
Published:February 19, 2016DOI:https://doi.org/10.1016/S1470-2045(15)00558-6
Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
Nobuyuki Katakami, et al.
Cancer. 2018 Feb 1; 124(3): 606–616.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814824/
(A) lean body mass and (B) body weight and (C) changes in primary and secondary efficacy measures from the baseline over 12 weeks.
小野薬品 がん悪液質用薬アナモレリンを国内申請 承認されれば初の治療薬に
公開日時 2018/11/28 03:51
https://www.mixonline.jp/Article/tabid/55/artid/65680/Default.aspx
cancer cachexiaだけでなく、pulmonary cachexia、cardiac cachexia、CNS lesion cachexiaなど除脂肪体重増加に期待するが治験は？
anamorelin (ONO‐7643)は新しいselective ghrelin receptor agonist
非がん患者含めてのシステマティック＆メタアナリシス
Two ghrelin receptor agonists for adults with malnutrition: a systematic review and meta-analysis
Jianhua Su, et al.
Nutr J. 2016; 15: 97. Published online 2016 Nov 16. doi: [10.1186/s12937-016-0214-5]
除脂肪体重増加確認されている
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112740/
(上から２番目は、透析患者・・・ J Am Soc Nephrol. 2005 Jul;16(7):2111-8. Epub 2005 May 11.）
以下は、非小細胞性肺癌NSCLC患者でのアナモレリンのRCT
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
Dr Jennifer S Temel, M et al.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00558-6/fulltext
Published:February 19, 2016DOI:https://doi.org/10.1016/S1470-2045(15)00558-6
Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
Nobuyuki Katakami, et al.
Cancer. 2018 Feb 1; 124(3): 606–616.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814824/
(A) lean body mass and (B) body weight and (C) changes in primary and secondary efficacy measures from the baseline over 12 weeks.
小野薬品 がん悪液質用薬アナモレリンを国内申請 承認されれば初の治療薬に
公開日時 2018/11/28 03:51
https://www.mixonline.jp/Article/tabid/55/artid/65680/Default.aspx
cancer cachexiaだけでなく、pulmonary cachexia、cardiac cachexia、CNS lesion cachexiaなど除脂肪体重増加に期待するが治験は？
コメント
コメントを投稿